Aethlon Medical (NASDAQ:AEMD) Earns Sell Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research note issued to investors on Wednesday. The brokerage set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Aethlon Medical in a research report on Monday.

Aethlon Medical Price Performance

Shares of NASDAQ:AEMD opened at $0.45 on Wednesday. Aethlon Medical has a 1 year low of $0.24 and a 1 year high of $1.85. The business has a 50 day simple moving average of $0.64 and a two-hundred day simple moving average of $0.50. The firm has a market capitalization of $6.51 million, a PE ratio of -0.28 and a beta of 1.80.

Aethlon Medical (NASDAQ:AEMD) last announced its earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.09. Equities research analysts expect that Aethlon Medical will post -0.73 EPS for the current fiscal year.

Institutional Trading of Aethlon Medical

Several institutional investors and hedge funds have recently modified their holdings of AEMD. Renaissance Technologies LLC bought a new stake in shares of Aethlon Medical during the fourth quarter valued at approximately $25,000. Allegiance Financial Group Advisory Services LLC bought a new stake in shares of Aethlon Medical during the fourth quarter valued at approximately $26,000. Sassicaia Capital Advisers LLC bought a new stake in shares of Aethlon Medical during the fourth quarter valued at approximately $31,000. Virtu Financial LLC bought a new stake in shares of Aethlon Medical during the fourth quarter valued at approximately $81,000. Finally, Boothbay Fund Management LLC bought a new stake in shares of Aethlon Medical during the fourth quarter valued at approximately $186,000. Institutional investors own 1.99% of the company’s stock.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.